Details
Stereochemistry | ACHIRAL |
Molecular Formula | C5H4N2O4.C4H11N5 |
Molecular Weight | 285.2599 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)C(=N)NC(N)=N.OC(=O)C1=CC(=O)NC(=O)N1
InChI
InChIKey=KIAVTTZIWJZMIP-UHFFFAOYSA-N
InChI=1S/C5H4N2O4.C4H11N5/c8-3-1-2(4(9)10)6-5(11)7-3;1-9(2)4(7)8-3(5)6/h1H,(H,9,10)(H2,6,7,8,11);1-2H3,(H5,5,6,7,8)
Molecular Formula | C5H4N2O4 |
Molecular Weight | 156.0963 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | C4H11N5 |
Molecular Weight | 129.1636 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://packageinserts.bms.com/pi/pi_glucophage.pdfCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25333032 | http://www.rsc.org/images/eic_nov2011_metformin_tcm18-210010.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22117616
Sources: https://packageinserts.bms.com/pi/pi_glucophage.pdf
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/25333032 | http://www.rsc.org/images/eic_nov2011_metformin_tcm18-210010.pdf | https://www.ncbi.nlm.nih.gov/pubmed/22117616
Metformin is the most widely used drug to treat type 2 diabetes, and is one of only two oral antidiabetic drugs on the World Health Organization (WHO) list of essential medicines.
Metformin is an antihyperglycemic agent which improves glucose tolerance in patients with type 2 diabetes, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. However, we still do not completely understand its mechanisms of action. The main effect of this drug from the biguanide family is to acutely decrease hepatic glucose production, mostly through a mild and transient inhibition of the mitochondrial respiratory chain complex I. In addition, the resulting decrease in hepatic energy status activates AMPK (AMP-activated protein kinase), a cellular metabolic sensor, providing a generally accepted mechanism for the action of metformin on hepatic gluconeogenesis. The use of metformin, the most commonly prescribed drug for type 2 diabetes, was repeatedly associated with the decreased risk of the occurrence of various types of cancers, especially of pancreas and colon and hepatocellular carcinoma.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006094 |
|||
Target ID: CHEMBL2363065 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22117616 |
|||
Target ID: CHEMBL2096907 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22117616 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | GLUCOPHAGE Approved UseMetformin hydrochloride tablets, USP is indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. Metformin hydrochloride extended-release tablets, USP is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Launch Date1995 |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
815.39 ng/mL |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: |
METFORMIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
7694.78 ng × h/mL |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: |
METFORMIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4.19 h |
750 mg single, oral dose: 750 mg route of administration: Oral experiment type: SINGLE co-administered: |
METFORMIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: HIGH-FAT |
Doses
Dose | Population | Adverse events |
---|---|---|
2550 mg 1 times / day steady, oral Recommended Dose: 2550 mg, 1 times / day Route: oral Route: steady Dose: 2550 mg, 1 times / day Sources: |
unhealthy, adult n = 141 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: adult Population Size: 141 Sources: |
Disc. AE: Diarrhea... AEs leading to discontinuation/dose reduction: Diarrhea (6%) Sources: |
850 mg 1 times / day steady, oral Recommended Dose: 850 mg, 1 times / day Route: oral Route: steady Dose: 850 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Disc. AE: Lactic acidosis... AEs leading to discontinuation/dose reduction: Lactic acidosis (grade 5) Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Diarrhea | 6% Disc. AE |
2550 mg 1 times / day steady, oral Recommended Dose: 2550 mg, 1 times / day Route: oral Route: steady Dose: 2550 mg, 1 times / day Sources: |
unhealthy, adult n = 141 Health Status: unhealthy Condition: type 2 diabetes mellitus Age Group: adult Population Size: 141 Sources: |
Lactic acidosis | grade 5 Disc. AE |
850 mg 1 times / day steady, oral Recommended Dose: 850 mg, 1 times / day Route: oral Route: steady Dose: 850 mg, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | |||
Page: - |
yes | yes (co-administration study) Comment: Co-administration of cimetidine, pyrimethamine, trimethoprim, lansoprazole, dolutegravir and vandetanib with metformin has been shown to increase its AUC by 1.2 to 1.7-fold Page: - |
PubMed
Title | Date | PubMed |
---|---|---|
[Marked creatine-phosphokinase elevation in myopathy after treatment with bezafibrate]. | 2000 Sep |
|
[Prevention of lactic acidosis due to metformin intoxication in contrast media nephropathy]. | 2000 Sep 30 |
|
Homocysteine and cardiovascular risk in patients with diabetes mellitus. | 2001 Apr |
|
Improved endothelial function with metformin in type 2 diabetes mellitus. | 2001 Apr |
|
Mechanism of fat-induced hepatic gluconeogenesis: effect of metformin. | 2001 Aug |
|
Management of diabetes mellitus in three settings in Jamaica. | 2001 Feb |
|
[Type 2 diabetes: what therapeutic strategy?]. | 2001 Feb 17 |
|
Beta-D-glycosylamidines: potent, selective, and easily accessible 1-glycosidase inhibitors. | 2001 Feb 26 |
|
Diabetes in elderly adults. | 2001 Jan |
|
Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. | 2001 Jan |
|
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia. | 2001 Jan |
|
A unique sialidase that cleaves the Neu5Gcalpha2-->5-O(glycolyl)Neu5Gc linkage: comparison of its specificity with that of three microbial sialidases toward four sialic acid dimers. | 2001 Jan 12 |
|
[Severe lactic acidosis due to metformin ingestion in a patient with contra-indication for metformin]. | 2001 Jan 13 |
|
Cholestatic jaundice associated with the use of metformin. | 2001 Jul |
|
Re: Contrast media-induced nephrotoxicity: identification of patients at risk and algorithms for prevention. | 2001 Jul |
|
Nateglinide. | 2001 Jul 1 |
|
Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection? | 2001 Jun |
|
Thiazolidinediones and liver toxicity. | 2001 Jun |
|
Management of type 2 diabetes. Evolving strategies for treatment. | 2001 Jun |
|
The effects of long-term metformin treatment on adrenal and ovarian steroidogenesis in women with polycystic ovary syndrome. | 2001 Jun |
|
Comparison of the metabolic effects of metformin and troglitazone on fructose-induced insulin resistance in male Sprague-Dawley rats. | 2001 Mar |
|
Rosiglitazone. | 2001 Mar |
|
Polycystic ovary syndrome and ovulation induction. | 2001 Mar |
|
Metformin and the polycystic ovary syndrome. | 2001 Mar |
|
Preparation and characterisation of rose Bengal-loaded surface-modified albumin nanoparticles. | 2001 Mar 12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://packageinserts.bms.com/pi/pi_glucophage.pdf
Recommended Dosing Schedule
Adults
The usual starting dose of GLUCOPHAGE Tablets is 500 mg twice a day or 850 mg once a day,
given with meals. In general, clinically significant responses are not seen at doses below 1500
mg per day. Dosage increases should be made in increments of 500 mg weekly or 850 mg every
2 weeks, up to a total of 2000 mg per day, given in divided doses. The dosage of
GLUCOPHAGE must be individualized on the basis of both effectiveness and tolerability.
Patients can also be titrated from 500 mg twice a day to 850 mg twice a day after 2 weeks. For
those patients requiring additional glycemic control, GLUCOPHAGE may be given to a
maximum daily dose of 2550 mg per day. Doses above 2000 mg may be better tolerated given
3 times a day with meals.
The usual starting dose of GLUCOPHAGE XR (metformin hydrochloride) Extended-Release
Tablets is 500 mg once daily with the evening meal. In general, clinically significant responses
are not seen at doses below 1500 mg per day. Dosage increases should be made in increments of
500 mg weekly, up to a maximum of 2000 mg once daily with the evening meal. The dosage of
GLUCOPHAGE XR must be individualized on the basis of both effectiveness and tolerability. If
glycemic control is not achieved on GLUCOPHAGE XR 2000 mg once daily, a trial of
GLUCOPHAGE XR 1000 mg twice daily should be considered. If higher doses of metformin
are required, GLUCOPHAGE should be used at total daily doses up to 2550 mg administered in
divided daily doses, as described above. (See CLINICAL PHARMACOLOGY: Clinical
Studies.)
Patients receiving GLUCOPHAGE treatment may be safely switched to GLUCOPHAGE XR
once daily at the same total daily dose, up to 2000 mg once daily. Following a switch from
GLUCOPHAGE to GLUCOPHAGE XR, glycemic control should be closely monitored and
dosage adjustments made accordingly (see CLINICAL PHARMACOLOGY: Clinical
Studies).
Pediatrics
The usual starting dose of GLUCOPHAGE is 500 mg twice a day, given with meals. Dosage
increases should be made in increments of 500 mg weekly up to a maximum of 2000 mg per day,
given in divided doses. The dosage of GLUCOPHAGE must be individualized on the basis of
both effectiveness and tolerability. Safety and effectiveness of GLUCOPHAGE XR in pediatric
patients have not been established.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23653391
Herein, our aim was to examine whether micromolar concentrations of metformin alone could bring about cancer cell death and whether micromolar metformin could increase the cytotoxic effect of commonly used chemotherapies in A2780 and SKOV3 cell lines and primary cultured cancer cells isolated from the peritoneal fluid of patients with advanced ovarian cancer. Our results in cell lines demonstrate that no significant loss of viability or change in cell cycle was observed with micromolar metformin alone; however, we observed cytotoxicity with micromolar metformin in combination with chemotherapy at concentrations where the chemotherapy alone produced no loss in viability.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:08:38 GMT 2023
by
admin
on
Fri Dec 15 18:08:38 GMT 2023
|
Record UNII |
KE1D8AP3J5
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
124097
Created by
admin on Fri Dec 15 18:08:38 GMT 2023 , Edited by admin on Fri Dec 15 18:08:38 GMT 2023
|
PRIMARY | |||
|
58840-24-7
Created by
admin on Fri Dec 15 18:08:38 GMT 2023 , Edited by admin on Fri Dec 15 18:08:38 GMT 2023
|
PRIMARY | |||
|
KE1D8AP3J5
Created by
admin on Fri Dec 15 18:08:38 GMT 2023 , Edited by admin on Fri Dec 15 18:08:38 GMT 2023
|
PRIMARY | |||
|
DTXSID30207560
Created by
admin on Fri Dec 15 18:08:38 GMT 2023 , Edited by admin on Fri Dec 15 18:08:38 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |